Investor Presentaiton

4 With Kerecis, Coloplast adds a long-term growth business, uniquely positioned to support Coloplast's long-term value creation Kerecis - financial assumptions KerecisⓇ . FY 2022/23 revenue growth of around 50% • Three-year revenue CAGR of around 30% until FY 2025/26 Attractive gross margin level, accretive to Coloplast, due to a cost- efficient production setup EBIT margin of around 10% in FY 2022/23 and around 20% in FY 2025/26. In the following years, the EBIT margin is expected to be in line with Coloplast's long-term guidance of more than 30% Our updated long-term financial guidance will drive continued long-term value creation through revenue and earnings growth کرا 100 Coloplast Accretive to Coloplast group organic growth with ~1%-point as of FY 2024/25 Short-term dilutive to the EBIT margin, with around 100 basis points impact p.a. (including PPA amortisation) in the Strive25 strategic period Transaction increasingly EPS accretive from FY 2026/27 Assumptions on long-term CAPEX ratio, NWC-to-sales, and tax rate are unchanged 8-10% organic growth p.a. more than 30% EBIT margin beyond 2024/251 1 For the remaining Strive25 strategic period running until end 2024/25, the EBIT margin is now expected to remain below 30%, and assumes dilution of around 100 basis points p.a. from Kerecis (including PPA amortisation) Coloplast

View entire presentation